EMA’s psychedelic workshop leaves stakeholders with as many questions as answers
Earlier this year, the EMA hosted a multi-stakeholder workshop to discuss regulatory issues surrounding drug development of psychedelic products. Despite intense interest in their use, no psychedelic products are approved in the European Regulatory Medicines Network, with drug developers facing legal and regulatory obstacles, including a dearth of guidance. EMA has now published a report on the workshop.
Fill out the form to read the full article.
Required *